These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 35156542)

  • 21. Prevalence and epidemiological associates of novel psychedelic use in the United States adult population.
    Sexton JD; Crawford MS; Sweat NW; Varley A; Green EE; Hendricks PS
    J Psychopharmacol; 2019 Sep; 33(9):1058-1067. PubMed ID: 30816808
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Psychedelic-Assisted Therapy: Emerging Treatments in Mental Health Disorders.
    Penn A; Dorsen CG; Hope S; Rosa WE
    Am J Nurs; 2021 Jun; 121(6):34-40. PubMed ID: 33993135
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The association of psychedelic use and opioid use disorders among illicit users in the United States.
    Pisano VD; Putnam NP; Kramer HM; Franciotti KJ; Halpern JH; Holden SC
    J Psychopharmacol; 2017 May; 31(5):606-613. PubMed ID: 28196428
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Self-Care Practices with Psychedelics - A Qualitative Study of Users' Perspectives.
    Soares CM; Leite Â; Pinto M
    J Psychoactive Drugs; 2023; 55(2):159-169. PubMed ID: 35574941
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Subtypes of the psychedelic experience have reproducible and predictable effects on depression and anxiety symptoms.
    Nikolaidis A; Lancelotta R; Gukasyan N; Griffiths RR; Barrett FS; Davis AK
    J Affect Disord; 2023 Mar; 324():239-249. PubMed ID: 36584715
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Psychedelics and virtual reality: parallels and applications.
    Aday JS; Davoli CC; Bloesch EK
    Ther Adv Psychopharmacol; 2020; 10():2045125320948356. PubMed ID: 32922734
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Crisis intervention related to the use of psychoactive substances in recreational settings--evaluating the Kosmicare Project at Boom Festival.
    Carvalho MC; de Sousa MP; Frango P; Dias P; Carvalho J; Rodrigues M; Rodrigues T
    Curr Drug Abuse Rev; 2014; 7(2):81-100. PubMed ID: 25563447
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Psychedelic Renaissance and Its Forensic Implications.
    Holoyda B
    J Am Acad Psychiatry Law; 2020 Mar; 48(1):87-97. PubMed ID: 31948993
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Experiences of microdosing psychedelics in an attempt to support wellbeing and mental health.
    Ryan RS; Copello A; Fox AP
    BMC Psychiatry; 2023 Mar; 23(1):160. PubMed ID: 36918852
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Among psychedelic-experienced users, only past use of psilocybin reliably predicts nature relatedness.
    Forstmann M; Kettner HS; Sagioglou C; Irvine A; Gandy S; Carhart-Harris RL; Luke D
    J Psychopharmacol; 2023 Jan; 37(1):93-106. PubMed ID: 36601974
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Motives and Side-Effects of Microdosing With Psychedelics Among Users.
    Hutten NRPW; Mason NL; Dolder PC; Kuypers KPC
    Int J Neuropsychopharmacol; 2019 Jul; 22(7):426-434. PubMed ID: 31152167
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Psychedelic Psychiatry and the Consult-Liaison Psychiatrist: A Primer.
    Barnett BS; Greer GR
    J Acad Consult Liaison Psychiatry; 2021; 62(4):460-471. PubMed ID: 34210406
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Public-Health-Based Vision for the Management and Regulation of Psychedelics.
    Haden M; Emerson B; Tupper KW
    J Psychoactive Drugs; 2016; 48(4):243-52. PubMed ID: 27430375
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Microdosing psychedelics: Demographics, practices, and psychiatric comorbidities.
    Rosenbaum D; Weissman C; Anderson T; Petranker R; Dinh-Williams LA; Hui K; Hapke E
    J Psychopharmacol; 2020 Jun; 34(6):612-622. PubMed ID: 32108529
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Does psychedelic drug use reduce risk of suicidality? Evidence from a longitudinal community-based cohort of marginalised women in a Canadian setting.
    Argento E; Strathdee SA; Tupper K; Braschel M; Wood E; Shannon K
    BMJ Open; 2017 Sep; 7(9):e016025. PubMed ID: 28939573
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparing Mental Health across Distinct Groups of Users of Psychedelics, MDMA, Psychostimulants, and Cannabis.
    Rougemont-Bücking A; Jungaberle H; Scheidegger M; Merlo MCG; Grazioli VS; Daeppen JB; Gmel G; Studer J
    J Psychoactive Drugs; 2019; 51(3):236-246. PubMed ID: 30836844
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predicting Responses to Psychedelics: A Prospective Study.
    Haijen ECHM; Kaelen M; Roseman L; Timmermann C; Kettner H; Russ S; Nutt D; Daws RE; Hampshire ADG; Lorenz R; Carhart-Harris RL
    Front Pharmacol; 2018; 9():897. PubMed ID: 30450045
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of psychedelics in the Czech Republic: results of recent population surveys.
    Chomynová P; Kočárová R; Kňažek F; Plevková M; Bláhová B; Valeš K; Mravčík V
    Cent Eur J Public Health; 2022 Sep; 30(3):144-153. PubMed ID: 36239361
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Epidemiology of hallucinogenic drug use in the Netherlands].
    van Laar MW; van Miltenburg CJA
    Tijdschr Psychiatr; 2020; 62(8):684-692. PubMed ID: 32816297
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.